Business Context and Reporting Period
Company: Astro-Med, Inc. (Note: Input metadata referenced "Astronova, Inc.", but the filing text identifies the registrant as Astro-Med, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: May 4, 2002
Business Overview: The company operates in three reporting segments: Test & Measurement (T&M), QuickLabel Systems (QLS), and Grass-Telefactor (G-T). The company manufactures and sells products for defense, aerospace, clinical, and research markets.
Key Financial Metrics
| Metric | Q1 2002 (Ended May 4) | Q1 2001 (Ended May 5) |
|---|---|---|
| Net Sales | $11,377,002 | $12,435,979 |
| Gross Profit | $3,808,425 | $5,052,093 |
| Gross Margin | 33.5% | 40.6% |
| Operating Income (Loss) | $(940,023) | $16,493 |
| Net Income (Loss) | $(632,255) | $149,675 |
| Diluted EPS | $(0.15) | $0.04 |
| Cash from Operations | $399,269 | $293,731 |
| Cash & Equivalents (End of Period) | $2,725,927 | $1,613,564 |
| Total Current Assets | $26,287,768 | N/A |
| Total Current Liabilities | $5,438,678 | N/A |
| Long-Term Debt (Current Maturities) | $12,559 | $24,755 |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9% year-over-year to $11.4 million. Domestic sales fell 7%, while international sales dropped 13%.
- Profitability Reversal: The company reported a net loss of $632,255 compared to a net income of $149,675 in the prior year. Operating income swung from a profit of $16,493 to a loss of $940,023.
- Margin Compression: Gross margin declined from 40.6% to 33.5% due to lower sales volume, unfavorable sales mix, and unabsorbed manufacturing overhead.
- Segment Performance:
- T&M: Sales down 11% due to shifts in defense spending; segment profit turned negative.
- QLS: Sales up 7% driven by printer/media growth, but segment profit turned negative due to sales mix changes.
- G-T: Sales down 24% due to hospital capital appropriation delays; segment profit turned negative.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 9% to $3.74 million, aided by the elimination of goodwill amortization. R&D expenses increased 11% to $1.01 million.
Guidance, Outlook, and Risks
- Backlog: New orders reached $12.7 million, a 2% increase over the prior year and an 8% improvement over the previous quarter, resulting in an unusually large backlog.
- Accounting Changes: The company adopted SFAS No. 142 (Goodwill), discontinuing goodwill amortization. It is currently conducting impairment reviews for goodwill, expected to be completed by the second quarter of fiscal 2003.
- Liquidity: Cash and securities available for sale totaled $5.94 million. The accounts receivable collection cycle improved to 56 days from 62 days. Inventory turns improved to 2.4 times.
- Risks: Key risks include declining demand in defense/aerospace markets, competition in specialty printers and neurophysiology, foreign currency exchange rate fluctuations, and delays in hospital capital spending.
- Dividends: The company declared and paid a quarterly dividend of $0.04 per share.
Investor Verification Checklist
- Goodwill Impairment: Verify the outcome of the ongoing goodwill impairment review under SFAS No. 142, as a write-down could significantly impact future earnings.
- Backlog Conversion: Monitor whether the reported increase in new orders ($12.7M) converts to revenue in subsequent quarters to offset the current sales decline.
- Segment Margins: Track the ability of the QLS and G-T segments to restore profitability given the current negative operating margins.
- Defense Spending Impact: Assess the long-term impact of the shift in defense spending from testing/research to counter-terrorism on the T&M segment.
- Cash Flow Sustainability: Confirm that operating cash flow remains positive despite the net loss, ensuring liquidity for operations and dividend payments.